Baseline characteristics in the SYNCHRONIZE ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ GLP ‐1 receptor dual agonist, for obesity in people with type 2 diabetes
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70263 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Sean Wharton und 9 weiteren Autor:innen. Beteiligte Einrichtung: McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boehringer Ingelheim.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Survodutide is an investigational glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist that has shown promise for treating obesity and its complications in Phase 2 trials. Two double‐blind, randomized, global Phase 3 trials are designed to assess the efficacy and safety of survodutide for treatment of obesity—SYNCHRONIZE™‐1 in people with obesity without type 2 diabetes (T2D) and SYNCHRONIZE™‐2 in people with obesity and T2D. This paper describes the baseline characteristics of participants in SYNCHRONIZE‐2 ( ClinicalTrials.gov identifier NCT06066528). Materials and Methods Participants aged ≥18 years with a body mass index (BMI) ≥27 kg/m 2 and T2D were randomized 1:1:1 to weekly subcutaneous survodutide (up‐titrated to 3.6 or 6.0 mg) or placebo with recommendations for modified diet and physical activity. The primary endpoints are the percentage change in body weight (BW) and achievement of BW reduction of ≥5% from baseline to Week 76.
Results
SYNCHRONIZE‐2 includes 752 treated participants from 133 sites across 19 countries. At baseline, participants had a mean age of 55.7 years, BMI 36.5 kg/m 2 , BW 104.1 kg, waist circumference 115.5 cm and haemoglobin A1c 7.4%; 50.7% were female. Overall, 36.2% are from Europe, 32.8% from North America and 22.3% from East Asia. The most common obesity complications included hypertension (69.0%), dyslipidaemia (67.6%), obstructive sleep apnoea (17.3%) and arteriosclerotic cardiovascular disease (10.9%); 78.7% were treated with metformin, 34.2% with sodium‐glucose co‐transporter‐2 inhibitors and 58.6% with lipid‐lowering medications.
Conclusions
SYNCHRONIZE‐2 will determine the efficacy, safety and tolerability of survodutide for BW reduction in people with obesity and T2D, whose baseline characteristics suggest a representative, diverse cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- McMaster University, Hamilton, Ontario, Canada.
- University of Toronto, Toronto, Ontario, Canada.
- University College Dublin School of Medicine, Dublin, Ireland.
- Ulster University, Coleraine, UK.
- Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, Houston, Texas, USA.
- Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Sean Wharton, Carel W le Roux, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Lee M Kaplan
Förderung
- Boehringer Ingelheim
Zitieren
APA
Wharton, S., le Roux, C. W., Bozkurt, B., Platz, E., Bleckert, G., Ajaz Hussain, S., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2026). Baseline characteristics in the SYNCHRONIZE ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ GLP ‐1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70263
Vancouver
Wharton S, le Roux CW, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, et al. Baseline characteristics in the SYNCHRONIZE ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ GLP ‐1 receptor dual agonist, for obesity in people with type 2 diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70263
BibTeX
@article{Wharton2026,
author = {Wharton, Sean and le Roux, Carel W and Bozkurt, Biykem and Platz, Elke and Bleckert, Gabriele and Ajaz Hussain, Samina and Brueckmann, Martina and Startseva, Elena and Kloer, Isabel M and Kaplan, Lee M},
title = {Baseline characteristics in the SYNCHRONIZE ™‐2 randomized phase 3 trial of survodutide, a glucagon receptor/ GLP ‐1 receptor dual agonist, for obesity in people with type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70263}
}
EUVIMED